Strong science, weak systems: Why European biotechs can't scale at home

European biotechs excel at scientific innovation but struggle to scale due to fragmented regulatory systems, limited venture capital funding compared to the US, and lack of experienced talent for growth and governance. The European Investment Bank aims to bridge funding gaps and take more risks than traditional VCs, while clearer regulatory pathways and support for clinical trials remain crucial for retaining and growing biotech companies within Europe.

This Wire brief sits within Fusion42's coverage of Biotech.